Related Experiment Videos
Gene combination raises broad human immunodeficiency virus-specific cytotoxicity
S A Calarota1, A Kjerrström, K B Islam
1Swedish Institute for Infectious Disease Control, Microbiology and Tumor Biology Center, Karolinska Institute, SE-171 82 Solna, Sweden.
Human Gene Therapy
|September 6, 2001
Summary
DNA plasmid vaccines combining HIV-1 genes (nef, rev, tat) boosted cellular immunity in patients. This immunization increased cytotoxic T lymphocyte precursors, showing potential for future HIV-1 therapies.
Area of Science:
- Immunology
- Virology
- Vaccine Development
Background:
- DNA plasmid vaccines offer a novel approach by allowing the combination of multiple genes.
- Traditional vaccines have limitations in combining genetic material for enhanced immune responses.
Purpose of the Study:
- To analyze the efficacy of a combination DNA plasmid vaccine encoding HIV-1 nef, rev, and tat regulatory genes.
- To assess the induction of cellular immune responses in asymptomatic HIV-1-infected patients with low pre-existing immunity.
Main Methods:
- Administered a combination DNA plasmid vaccine (nef, rev, tat) to HIV-1 patients.
- Evaluated MHC class I-restricted cytolytic activities and bystander effects.
- Assessed cytotoxic T lymphocyte (CTL) precursor induction using pseudovirus HIV-1/MuLV and vaccinia virus-infected target cells.
Main Results:
- Patients developed MHC class I-restricted cytolytic activities and enhanced bystander effects.
- A significant increase in CTL precursors targeting cells infected with the whole HIV-1 genome was observed.
- In vitro assessment confirmed consistency between gene product expression and in vivo CTL responses.
Conclusions:
- Combination DNA plasmid immunization effectively induces cellular immune responses, including CTL precursors, in HIV-1 patients.
- This approach shows promise for therapeutic applications in HIV-1 infection, potentially measurable through structured therapy interruption.
- No adverse clinical effects were noted during the study period.